Vabysmo

Faricimab

Neovascular (wet) age-related macular degeneration (nAMD). Diabetic macular edema (DME).

6 mg intravitreal inj every 4 wk (mthly) for 1st 4 doses. nAMD Followed by every 16 wk (4 mthly) if no disease activity. Consider treatment every 8 or 12 wk in patient w/ disease activity. DME Dosing interval may be extended up to every 16 wk (4 mthly) in increments up to 4 wk. Consider interval reduction if anatomic &/or visual outcomes deteriorate.

Hypersensitivity. Ocular or periocular infections; active intraocular inflammation.

Intravitreal inj-related reactions eg, endophthalmitis. Not to inj while IOP ≥30 mmHg. Withheld in patients w/ rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break; treatment-related decrease in best corrected visual acuity ≥30 letters compared w/ last assessment of visual acuity; subretinal haemorrhage involving centre of fovea or ≥50% total lesion area; performed or planned intraocular surgery w/in previous or next 28 days. Risk factors for retinal pigment epithelial (RPE) tears in nAMD; sustained dosing intervals ≤8 wk; risk of immunogenicity; signs of intraocular inflammation includes vision loss, eye pain, increased light sensitivity, floaters or worsening eye redness. Arterial thromboembolic events; risk of bilateral ocular adverse event due to bilateral treatment. Not to be administered concurrently w/ other anti-VEGF medicinal products in same eye. May affect ability to drive & use machines. Women of childbearing potential should use contraception during & for at least 3 mth following last dose. Not to be used during pregnancy. Lactation. Ped patients.

Cataract. Conjunctival hemorrhage, increased IOP & lacrimation, vitreous floaters, RPE tear (nAMD only), eye pain.

Not to be administered concurrently w/ other systemic or ocular anti-VEGF medicinal products.

Other Eye Preparations

S01LA09 - faricimab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

B